Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OCAT Mario Gabelli billionaire OCAT shareholder attracts money. "money attracts money"
First Silicon Valley A rated Bank and now a billionaire supporting institutions holding OCAT. next more and more abundance is how it works, money atracts money, it is "not" a peanut mindset.
Billionaires buying OCAT are bright. Did elyse sell half of his shares while a billionaire was buying them? Who supports the science and those afflicted in need. Billionaires? Institutions? For that matter, why would Astellas be interested at all in OCAT?
The OCAT science has advanced in the last ten years. Although some have slandered OCAT science and the Lancet Journal.
quote: "Lancet/Smanset/Have a Gansett-imo irrelevant and totally meaningless at this juncture!"
Lancet Peer Reviewed Journal recorded OCAT success. Best OCAT patient went from 20/400 to 20/40
Lancet Scientific Journal Peer Reviewed is reason for a much higher valuation. There is reason for billionaires and institutions to purchase shares of OCAT. Some think they are more financially savy than institutions and billionaires that are buying OCAT shares.
Billionaires and have a mindset of abundance. IMO
Wishful thinking to get off that easy.
First Korean's CHA interested then Japan's Astellas OCAT-interested.
What next? China? More billionaires? Up'd offer's?
Billionaire buying-big into OCAT along with institutions. :)
"Gabelli is paid via "incentive-based management fee"
"Based on recent regulatory filings, Mario Gabelli's only compensation is a 10% of pre-tax profits incentive-based management fee. He is not paid a base salary and does not receive stock options or restricted award."
Thankyou Lasers
If REGN and CHA are not compatible with Astellas, anything could happen.
How many times do i have to tell you that last minute offers do not come in the first minutes? Not saying a higher offer will or will not come in. $100.00 share valuation is very much within reason based on the facts in my last post. Again, not saying valuation should be $100.00 or should not be $100.00 fat lady has not sung
When i look at the REGN long-term chart it seems unlikely that they could do so well, however, congratulations to them. OCAT has also done something special that REGN has not done, leaving room for thought. OCAT to $100.00 looks like peanuts compared to REGN that has not done better science than OCAT but has greatly slowed the degrading in the eye while OCAT has stopped and improved the condition. "fact"
http://ih.advfn.com/stock-market/NASDAQ/regeneron-pharmaceuticals-inc-mm-REGN/stock-price
i do not mind if they think or pretend to think different, however, OCAT success in the Lancet Scientific Journal Peer Reviewed is reason for a much higher valuation. Those that bet against OCAT/ACT had to cover IMO and were not prepared.
Shiskabill, a friend bought in at $20.00 so it is imperative to me for a higher valuation.
The fact that tender turned down means something, shows shareholders value OCAT higher.
OCAT could go higher and has before.
Happy new year 2016 to IHUB OCAT family.
Hope the new year changes the course of Ocata for good per our wishes and hopes.
"factual OCAT nuggets"
Quote of questions?
questions are:
"1) How would the Deleware court value the company if the cowboy and other patients were to share how this treatment improved their lives?
2) How do they value over 50% of the lancet reported patients (18) gaining 3-5 lines of VA for a disease that has no treatment?
3) How do they value a company with these early human results where just the AMD/SMD Market Opportunity in the US and UK alone is $300,000,000,000 (30M people afflicted X a possible treatment cost of just $10,000)
4) How do they value a company that was deeply shorted for nearly a year leading up to the buyout when 12 months prior the market valued the company at 12 pps?
5) How do they value a company with 150 current and pending patents that virtual control hundreds of cells derived from a blastomere or IPSC?
6) How will the court value a company that has published papers and much pre-clinical results that show MS, Lupus and Crohn's disease were nearly reversed in mice, rats and canines?
7) How does the court value a company that has never shared any patient results with shareholders on the 12 UK patients in almost 4 years since the initial patient was treated?"
information comes from BF ICELL
OCAT has millions in cash, backing from Silicon-Valley-A-rated-Bank-and millions of customers for the needed science recorded in the peer reviewed Lancet Scientific Journal.
OCAT deserves stacks of green for supporting and developing a game changing science proven in the Lancet Peer Reviewed Journal helping macular degeneration patents greatly documented massive improvment 20/40 from 20/400. Also, chrons success and several other developments.
BigWorm129 there is a silver-lining somewhere behind your-well-expressed-thoughts. Thank-you!!!
A few here do not want abundance, why does OCAT have so much? For those in the right place at the right time wishing the best.
Reality may very well be stranger than fiction. The Lancet Journal and the five testing hospital institutions tip things in favor of "science support".
Those that did not want to support and tell of the patients benefits of having OCAT science have freely chosen that position for their own reasons.
For those that have freely undermined for years and said OCAT was going to zero, your choice was made with or without coersion. Recorded for all that can see even just a little bit.
For the thousands of supporters of the patients and the science, you have my up most respect for your moral and ethical stance. .... "true humanity representation"
Thank God that OCAT is in the right-place at the right time. Taxpayers are over-burdened and OCAT can fill many needs. The OCAT purpose in helping the afflicted is great. The priority ahead of the intended OCAT goals in helping the afflicted are real and opportunity benefits abound. Why does OCAT have so much?
Some people are willing and able to reach their goals through all the uncertainty by staying focused. Why does OCAT have so much?
I can stay focused on my clear-OCAT goals and i choose my own attitude.
Why does OCAT have so much? Without Astellas I can say this that there are many ways to move further ahead in the financial ways as well as the medical advancements. Astellas upping the bid is only one of the many possibilities ahead, so many combinations and possibilities known and unknown to bridge from today's situation.
Why is OCAT so wealthy with great scientist, millions in the bank and a long list of "Intellectual Property" pertaining to the health of millions of people? Thankfully we have come along way from past success that was in rodents only which was great and now we have success in "humans" over many years of safety and improvement. I can say this that there are many ways to move further ahead in the financial ways as well as the medical advancements.
Last-minute bidding-wars do not happen in the first-minute. OCAT has great methods lined up to help people. Without blood on their hands like other methods and companies. OCAT olso has other ways they can go without bidding wars.
If Pfizer, Novartis, Merck, J&J or Sanofi and others could licence OCAT's patented cell therapy, they could develope many new technologies without "blood on their hands".
Astellas crawl's on eggshells while Regeneron walks upright on treasure. OCAT has the IP of the future and welcomes treasure.
Astellas was given a fair chance.
OCAT shareholders birthright to abundance and healing to the afflicted is written in the IP. Seen and unseen abundance/healing is welcomed, allowed and appreciated.
Congradulations to Regenerons wealth/healing creation.
OCAT supporting shareholders are worthy of all the IP's abundance that is-was-or-will be.
OCAT's patents are regenerative medicines future. Lowering taxpayers-healthcare-cost by improving patients. "Sep 9, 2015 ... ... First Patient Enrolled in Ocata Therapeutics' Phase 2 Study"
"Something good is happening" What could we here next?
OCAT has scientific momo. Conclusion
"Cornea transplantation is one of the most successful organ transplantations with a relatively low risk of rejection. The gold standard of care for corneal endothelial disease is hampered by a lack of donor corneas, leaving many patients with visual defects and blindness. The ability to produce high quality corneal endothelial cells from human embryonic stem cells would improve access to cornea transplantation worldwide. Here we present a simple and robust method for generating scalable amounts of hESC-CEC for transplantation. We have characterized the morphology, localization and expression of key corneal endothelial proteins, and gene expression by QPCR and microarray analysis indicating that the hESC-CEC were highly similar to adult CEC. Although beyond the scope of this paper, future experiments include the transplantation of the hESC-CEC in animal models of corneal edema to test the function of the hESC-CEC. hESC-derived CEC could provide a viable alternative to the use of donor corneas for corneal endothelial cell disease."
Something good is happening i can feel it in my bones.
quote: "Is OCAT's successful cell therapy of 31 out of 31 patients now with stable or improved vision of great importance? Got to love the benefits for AMD and SMD patients and the patents held."
Astellas values OCAT at, at least $8.50 for OCAT's successful "DATA" recorded in the Lancet Peer Reviewed Scientific Journal. The possibility of a higher offer is an option to potentially happen here along with a "potential" higher bidder. The fact that round one offer for $8.50 was successfully turned down by the majority of shareholders "40,000"? means that shareholders value OCAT higher than $8.50. A few supposed shareholders here do not like anyone to value OCAT higher for obvious reasons even though OCAT/ACT went much higher in the past at a time with much less recorded success than OCAT has "NOW" currently developed and at a time it went much higher with less recorded patents.